(NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...

NeoGenomics shows strong clinical revenue growth and positive technical momentum, but faces significant profitability and cash flow challenges. The valuation remains a concern due to negative earnings ...

NeoGenomics Inc. (NEO), which provides cancer-focused genetic testing and contract research, has agreed to acquire Inivata Limited. Inivata is a commercial-stage liquid biopsy platform provider.

NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

Management raised full-year 2025 revenue guidance to $747 million-$759 million, reflecting 13%-15% growth. Adjusted EBITDA guidance remains unchanged at $55 million-$58 million. Pathline is projected ...

NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

NeoGenomics (NEO), a Fort Myers-based cancer testing and research lab, surprised Wall Street Monday with higher-than-expected third-quarter revenue and break-even earnings per share. The company ...

Forbes contributors publish independent expert analyses and insights. #1 stock picker for 51 straight months on SumZero. AI is my edge. The Most Attractive Stocks (+2.2%) underperformed the S&P 500 ...

Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests. The slowdown is ...